Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.50 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.45 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.91 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.91 |
| ▸ | CASP1 | P29466 | 1/20 | 0.91 |
| ▸ | CASP7 | P55210 | 1/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL39679 | 1.00 | CYP3A4 (0.91) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3134351 | 1.00 | CYP3A4 (0.91) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL39680 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL269980 | 1.00 | CYP3A4 (0.91) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9099015 | 1.00 | CYP3A4 (0.91) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6753846 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30108424 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5964581 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21523286 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7154212 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9448239-B2 | Monoclonal antibodies against PCBP-1 antigens, and uses therefor | ALPER BIOTECH LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20140178906-A1 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR | ALPER BIOTECH LLC. | 2014-06-26 | — | — | US | disclosed |
| US-20140147858-A1 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR | ALPER BIOTECH, LLC (US) | 2014-05-29 | — | — | US | disclosed |
| US-8703441-B2 | Monoclonal antibodies against PCBP-1 antigens, and uses therefor | ALPER BIOTECH, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8609096-B2 | Monoclonal antibodies against PCBP-1 antigens, and uses therefor | ALPER BIOTECH, LLC (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2667715-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERES USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | Neuren Pharmaceuticals Limited (NZ) | 2013-12-04 | — | — | EP | disclosed |
| US-8540991-B2 | Monoclonal antibodies against PCBP-1 antigens, and uses therefor | ALPER BIOTECH, LLC (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130189705-A1 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR | ALPER BIOTECH, LLC (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190204-A1 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR | ALPER BIOTECH, LLC | 2013-07-25 | — | — | US | disclosed |
| EP-2596365-A2 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR | Alper Biotech, Llc (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-0666987-A4 | MEASUREMENT OF TOTAL MOLECULE IN A SAMPLE AND METHODS BASED THEREON. | T CELL DIAGNOSTICS INC (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996038463-A1 | DNA SEQUENCE AND ENCODED MAMMARY-SPECIFIC BREAST CANCER PROTEIN | WASHINGTON UNIVERSITY (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0666987-A1 | MEASUREMENT OF TOTAL MOLECULE IN A SAMPLE AND METHODS BASED THEREON | T Cell Diagnostics, Inc. (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0575522-A4 | POLYPEPTIDES DERIVED FROM THE HUMAN IMMUNODEFICIENCY VIRUS ENDONUCLEASE PROTEIN. | JOHNSON & JOHNSON (US) | 1994-11-23 | — | — | EP | disclosed |
| WO-1994010571-A1 | MEASUREMENT OF TOTAL MOLECULE IN A SAMPLE AND METHODS BASED THEREON | T CELL SCIENCES, INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0575522-A1 | POLYPEPTIDES DERIVED FROM THE HUMAN IMMUNODEFICIENCY VIRUS ENDONUCLEASE PROTEIN | JOHNSON & JOHNSON (US) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992016219-A1 | POLYPEPTIDES DERIVED FROM THE HUMAN IMMUNODEFICIENCY VIRUS ENDONUCLEASE PROTEIN | JOHNSON & JOHNSON (US) | 1992-10-01 | — | — | WO | disclosed |
| US-4434227-A | PREVENTION OF BINDING OF RHEUMATOID FACTOR | ABBOTT LABORATORIES (US) | 1984-02-28 | — | — | US | disclosed |
| EP-0097573-A1 | Device for the determination of a biological component, process for its manufacture and its use in an assay procedure | Société anonyme: COMPAGNIE ORIS INDUSTRIE (FR) | 1984-01-04 | — | — | EP | disclosed |
| US-4069052-A | Color photographic materials with spiro heterocyclic stabilizing agents comprising 2-imidazolidine-4',5'-dione rings | AGFA-GEVAERT AKTIENGESELLSCHAFT (DT) | 1978-01-17 | — | — | US | disclosed |